Amivantamab Plus Chemotherapy with and without Lazertinib in EGFR-mutant NSCLC
1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazertinib–chemotherapy group, and 4.2 months for...
Concurrent stereotactic radiation with antibody-drug conjugates in the treatment of brain metastases is associated with a greater risk of symptomatic radiation necrosis
1. A greater percentage of patients who received concurrent stereotactic radiation therapy with antibody-drug conjugates manifested severe levels of radiation...
Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ±...
Treatment of metastatic uveal melanoma with tebentafusp provides greater overall survival and progression-free survival as compared to standard treatment options
1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse...
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR...
Berzosertib Plus Topotecan vs Topotecan Alone in Relapsed Small Cell Lung Cancer
1 .The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was...
Adenocarcinoma is the most prevalent lung cancer subtype and has a greater incidence rate in males than females
1. The second greatest burden of lung cancer worldwide is attributed to squamous cell carcinoma 2. Large cell carcinoma represents...
Maintenance Olaparib Rechallenge in Platinum-Sensitive Relapsed Ovarian Cancer
1. Median PFS was improved in the olaparib arm vs placebo, with an HR 0.57 in the BRCAm cohort and...
Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort....
Omission of axilla surgery is non-inferior to sentinel lymph node biopsy in female patients with small breast cancers and clinically negative axillary lymph nodes
1. 5-year distant disease-free survival was comparable between both groups. 2. 5-year overall survival was similar between groups. Evidence Rating...
